LOGIN
ID
PW
MemberShip
2025-09-10 06:04
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Gov't begins patient advocacy service for medical incidents
by
Lee, Jeong-Hwan
May 15, 2025 06:24am
The Ministry of Health and Welfare (MOHW) will start implementing the 'patient advocacy service,' which provides a legal representative matching service for mediating disputes to strengthen the rights of patients who are victims of medical incidents, effective this month (May). The service supports the conflict between a patient and a medi
Policy
Reimb of comb cancer therapies w/o detailed criteria
by
Lee, Tak-Sun
May 14, 2025 06:09am
The reimbursement policy for combination cancer therapies, announced this month, has been implemented without detailed criteria, causing further confusion in medical practices. This was contributed by the Ministry of Health and Welfare (MOHW) and the Health Insurance Review and Assessment Service (HIRA), which had differing schedules for revi
Policy
CDRC to talk partial reimb details for comb cancer therapy
by
Lee, Tak-Sun
May 13, 2025 06:06am
An additional date has been set to discuss detailed criteria regarding partial reimbursement of combination cancer therapy, as announced this month. The Health Insurance Review and Assessment Service (HIRA) has decided to convene another Cancer Drug Review Committee (CDRC) meeting, which was not scheduled. According to industry sources
Policy
Reimb expansion for Benlysta in negotiations with NHIS
by
Lee, Tak-Sun
May 12, 2025 05:59am
Negotiations are underway to expand reimbursement for Benlysta (belimumab, GSK), a treatment for active systemic lupus erythematosus in adults. The drug was added to the reimbursement list in 2021 through the risk-sharing agreement (RSA), 8 years after its approval in Korea in 2013. According to industry sources on the 9th, the Nationa
Policy
Fitusiran for hemophilia receives orphan drug designation
by
Lee, Hye-Kyung
May 9, 2025 06:01am
A long-acting treatment for all types of hemophilia, administered every 2 months, has been designated as an orphan drug in South Korea. According to the ¡°Regulations on the Designation of Orphan Drugs¡± released by the Ministry of Food and Drug Safety on the 7th, Sanofi's Fitusiran was designated as the 386th orphan drug in Korea. Fitusi
Policy
Ofev reimbursed from May... inflow of generic versions
by
Lee, Hye-Kyung
May 9, 2025 05:59am
The generic drug market is growing for Boehringer Ingelheim's idiopathic pulmonary fibrosis treatment ¡®Ofev Soft Capsules (nintedanib),¡¯ which was granted reimbursement and was listed from this month, 8 years after approval. On the 7th, the Ministry of Food and Drug Safety approved 2 items, 100 mg and 150 mg of Whan In Pharm¡¯s ¡®Ofenip
Policy
Drug-switching to AZ Ultomiris increases with aHUS reimb
by
Lee, Tak-Sun
May 7, 2025 06:02am
Drug switching for atypical Hemolytic Uremic Syndrome (aHUS) has become common practice. As 'Ultomiris (ravulizumab)' becomes reimbursed as of January in addition to previously reimbursed 'Soliris (eculizumab),' patients on Soliris are switching to Ultomiris. Two drugs are pre-reviewed medications distributed by AstraZeneca. According
Policy
Increasing requests for BESREMi reimbursement
by
Whang, byung-woo
May 7, 2025 06:02am
Whether the polycythemia vera (PV) treatment BESREMi (ropeginterferon alfa-2b) will be considered for the Drug Reimbursement Evaluation Committee (DREC) review gains attention. According to the pharmaceutical industry sources, the 5th DREC of the Health Insurance Review & Assessment Service (HIRA) is scheduled to convene on the 8th. BES
Policy
Reimb for ovarian cancer treatment lacks full coverage
by
Whang, byung-woo
May 2, 2025 05:56am
Despite expanded reimbursement for homologous recombinant deficiency (HRD)-positive ovarian cancer, HRD-related tests remain non-reimbursed. The Korean medical community has taken the initiative to resolve this issue. Sources reported that the Korean Society of Gynecologic Oncology is collecting evidence to propose reimbursing the HRD test
Policy
Ofev will be reimbursed next month
by
Lee, Tak-Sun
Apr 29, 2025 05:57am
Ofev Soft Cap (nintedanib esylate, Boehringer Ingelheim Korea) , which was approved in South Korea in 2016, will be listed for reimbursement next month, creating an opportunity for follow-on drugs. It took a long time to secure reimbursement, and with its compound patent already expired, generic manufacturers have obtained marketing autho
<
11
12
13
14
15
16
17
18
19
20
>